345 related articles for article (PubMed ID: 32086342)
1. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
[TBL] [Abstract][Full Text] [Related]
2. RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
Kohlmeyer JL; Kaemmer CA; Umesalma S; Gourronc FA; Klingelhutz AJ; Quelle DE
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065204
[TBL] [Abstract][Full Text] [Related]
3. CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.
Kohlmeyer JL; Lingo JJ; Kaemmer CA; Scherer A; Warrier A; Voigt E; Raygoza Garay JA; McGivney GR; Brockman QR; Tang A; Calizo A; Pollard K; Zhang X; Hirbe AC; Pratilas CA; Leidinger M; Breheny P; Chimenti MS; Sieren JC; Monga V; Tanas MR; Meyerholz DK; Darbro BW; Dodd RD; Quelle DE
Clin Cancer Res; 2023 Sep; 29(17):3484-3497. PubMed ID: 37410426
[TBL] [Abstract][Full Text] [Related]
4. Combination therapies for MPNSTs targeting RABL6A-RB1 signaling.
Kohlmeyer JL; Gordon DJ; Tanas MR; Dodd RD; Monga V; Darbro BW; Quelle DE
Oncotarget; 2021 Jan; 12(1):10-14. PubMed ID: 33456709
[TBL] [Abstract][Full Text] [Related]
5. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
6. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.
Umesalma S; Kaemmer CA; Kohlmeyer JL; Letney B; Schab AM; Reilly JA; Sheehy RM; Hagen J; Tiwari N; Zhan F; Leidinger MR; O'Dorisio TM; Dillon J; Merrill RA; Meyerholz DK; Perl AL; Brown BJ; Braun TA; Scott AT; Ginader T; Taghiyev AF; Zamba GK; Howe JR; Strack S; Bellizzi AM; Narla G; Darbro BW; Quelle FW; Quelle DE
J Clin Invest; 2019 Mar; 129(4):1641-1653. PubMed ID: 30721156
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo.
Kohlmeyer JL; Kaemmer CA; Lingo JJ; Voigt E; Leidinger MR; McGivney GR; Scherer A; Koppenhafer SL; Gordon DJ; Breheny P; Meyerholz DK; Tanas MR; Dodd RD; Quelle DE
Neurooncol Adv; 2022; 4(1):vdac047. PubMed ID: 35571990
[TBL] [Abstract][Full Text] [Related]
8. Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.
Shih TC; Fan Y; Kiss S; Li X; Deng XN; Liu R; Chen XJ; Carney R; Chen A; Ghosh PM; Lam KS
Neuro Oncol; 2019 Nov; 21(11):1389-1400. PubMed ID: 31127849
[TBL] [Abstract][Full Text] [Related]
9. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.
Beck TN; Georgopoulos R; Shagisultanova EI; Sarcu D; Handorf EA; Dubyk C; Lango MN; Ridge JA; Astsaturov I; Serebriiskii IG; Burtness BA; Mehra R; Golemis EA
Mol Cancer Ther; 2016 Oct; 15(10):2486-2497. PubMed ID: 27507850
[TBL] [Abstract][Full Text] [Related]
10. Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.
Gampala S; Shah F; Zhang C; Rhodes SD; Babb O; Grimard M; Wireman RS; Rad E; Calver B; Bai RY; Staedtke V; Hulsey EL; Saadatzadeh MR; Pollok KE; Tong Y; Smith AE; Clapp DW; Tee AR; Kelley MR; Fishel ML
Br J Cancer; 2021 Apr; 124(9):1566-1580. PubMed ID: 33658640
[TBL] [Abstract][Full Text] [Related]
11. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
[TBL] [Abstract][Full Text] [Related]
12. RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner.
Hagen J; Muniz VP; Falls KC; Reed SM; Taghiyev AF; Quelle FW; Gourronc FA; Klingelhutz AJ; Major HJ; Askeland RW; Sherman SK; O'Dorisio TM; Bellizzi AM; Howe JR; Darbro BW; Quelle DE
Cancer Res; 2014 Nov; 74(22):6661-70. PubMed ID: 25273089
[TBL] [Abstract][Full Text] [Related]
13.
Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT
Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
16. Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.
Kim JY; Jayne LA; Bai Y; Feng MJHH; Clark MA; Chung S; W Christman J; Cianciolo RE; Pabla NS
Biochem Pharmacol; 2020 Jul; 177():113939. PubMed ID: 32229099
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer.
Dang F; Nie L; Zhou J; Shimizu K; Chu C; Wu Z; Fassl A; Ke S; Wang Y; Zhang J; Zhang T; Tu Z; Inuzuka H; Sicinski P; Bass AJ; Wei W
Nat Commun; 2021 Sep; 12(1):5386. PubMed ID: 34508104
[TBL] [Abstract][Full Text] [Related]
18. Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts.
Butler E; Schwettmann B; Geboers S; Hao G; Kim J; Nham K; Sun X; Laetsch TW; Xu L; Williams NS; Skapek SX
Pediatr Blood Cancer; 2020 Dec; 67(12):e28639. PubMed ID: 32975370
[TBL] [Abstract][Full Text] [Related]
19. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Sheng J; Kohno S; Okada N; Okahashi N; Teranishi K; Matsuda F; Shimizu H; Linn P; Nagatani N; Yamamura M; Harada K; Horike SI; Inoue H; Yano S; Kumar S; Kitajima S; Ajioka I; Takahashi C
Hepatology; 2021 Oct; 74(4):1971-1993. PubMed ID: 33931882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
